Back Home
  • Home
  • The Company
    • How we work
    • History
    • Group Structure
    • Management Team
    • Board of Directors
  • Technology
    • The ExpreS2 Platform
      • About S2 cells
      • ExpreS2 Kit
      • Transfection Reagents
      • FAQs
    • Vaccines
      • Placental Malaria Vaccine
      • Blood Stage Malaria Vaccine
      • Other Malaria work
  • Services
    • Custom Proteins and R&D Reagents
    • Process Development
    • Feasibility Studies
    • Licensing
  • Investor
    • Pressmeddelanden (SE)
    • Press Releases (EN)
    • Other News
    • Financial Calendar
    • Shareholder Information
    • Reports & Presentations
    • IPO
    • Nyemission 2017
    • Nyemission 2018
    • Bolagsbeskrivning
    • Bolagsstyrning
    • Investor Relations
    • Bolagsstämma
  • News
    • Pressmeddelanden (SE)
    • Press Releases (EN)
    • Subscribe to News
    • Other News
    • Publications
    • Meet Us
  • Contact
  • Pressmeddelanden (SE)
  • Press Releases (EN)
  • Financial Calendar
  • Shareholder Information
  • IPO
  • Nyemission 2017
  • Nyemission 2018
  • Reports & Presentations
  • Bolagsstyrning
  • Bolagsbeskrivning
  • Investor Relations
  • Bolagsstämma

Nyemission 2017

 

Swedish

  • Memorandum 2017(pdf)
  • Teaser 2017(pdf)
  • Anmälningssedel  2017(pdf)

 

English Translations

In case of any discrepancies to the Swedish original, the Swedish text shall prevail

  • Teaser 2017(pdf)
  • Subscription form 2017(pdf)

 



ExpreS2ion Biotechnologies
Agern Allé 1, DK-2970 Horsholm, Denmark
E-mail: info@expres2ionbio.com 
Phone: +45 2222 1019

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Got it! Read more about cookies in our Privacy Policy
Terms & General Conditions | Legal Notice & Disclaimer

Follow Us

· © 2018 ExpreS2ion Biotechnologies · Powered by · Designed with the Customizr theme ·

Back to top